Comerica Bank increased its holdings in Thermo Fisher Scientific Inc (NYSE:TMO) by 0.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 157,589 shares of the medical research company’s stock after purchasing an additional 899 shares during the period. Comerica Bank’s holdings in Thermo Fisher Scientific were worth $30,260,000 as of its most recent SEC filing.
A number of other hedge funds have also recently bought and sold shares of TMO. BlackRock Inc. grew its position in Thermo Fisher Scientific by 2,692.1% during the first quarter. BlackRock Inc. now owns 22,988,885 shares of the medical research company’s stock valued at $3,531,095,000 after acquiring an additional 22,165,530 shares during the period. Capital Research Global Investors grew its position in Thermo Fisher Scientific by 29.8% during the second quarter. Capital Research Global Investors now owns 17,304,897 shares of the medical research company’s stock valued at $3,019,185,000 after acquiring an additional 3,973,136 shares during the period. Janus Henderson Group PLC grew its position in Thermo Fisher Scientific by 2,058.1% during the second quarter. Janus Henderson Group PLC now owns 2,342,046 shares of the medical research company’s stock valued at $408,620,000 after acquiring an additional 2,233,522 shares during the period. Veritas Asset Management LLP lifted its stake in shares of Thermo Fisher Scientific by 112.4% during the second quarter. Veritas Asset Management LLP now owns 2,430,759 shares of the medical research company’s stock worth $424,095,000 after purchasing an additional 1,286,259 shares in the last quarter. Finally, Harbour Capital Advisors LLC lifted its stake in shares of Thermo Fisher Scientific by 18,197.5% during the second quarter. Harbour Capital Advisors LLC now owns 1,201,051 shares of the medical research company’s stock worth $6,884,000 after purchasing an additional 1,194,487 shares in the last quarter. 86.16% of the stock is owned by hedge funds and other institutional investors.
In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $188.39, for a total transaction of $9,419,500.00. Following the sale, the chief executive officer now owns 252,577 shares in the company, valued at $47,582,981.03. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.49% of the company’s stock.
A number of research analysts have commented on TMO shares. Cowen restated an “outperform” rating and set a $220.00 price objective (up previously from $200.00) on shares of Thermo Fisher Scientific in a research note on Sunday, September 10th. Leerink Swann boosted their price objective on Thermo Fisher Scientific from $190.00 to $207.00 and gave the stock an “outperform” rating in a research note on Monday, October 9th. Deutsche Bank set a $226.00 price objective on Thermo Fisher Scientific and gave the stock a “buy” rating in a research note on Thursday, October 26th. Zacks Investment Research cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. Finally, Goldman Sachs Group started coverage on Thermo Fisher Scientific in a research note on Tuesday, September 26th. They set a “buy” rating and a $225.00 price objective on the stock. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $205.21.
Thermo Fisher Scientific Inc (NYSE TMO) traded down $10.17 during trading hours on Tuesday, hitting $182.03. The company had a trading volume of 3,926,700 shares, compared to its average volume of 1,555,471. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.81 and a current ratio of 1.26. Thermo Fisher Scientific Inc has a fifty-two week low of $139.88 and a fifty-two week high of $201.20. The firm has a market capitalization of $77,071.31, a PE ratio of 21.12, a price-to-earnings-growth ratio of 1.76 and a beta of 1.06.
Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 25th. The medical research company reported $2.31 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. The business had revenue of $5.12 billion for the quarter, compared to analysts’ expectations of $5.03 billion. During the same quarter in the previous year, the firm posted $2.03 earnings per share. The company’s revenue was up 13.9% compared to the same quarter last year. equities research analysts expect that Thermo Fisher Scientific Inc will post 9.36 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Monday, January 15th. Investors of record on Friday, December 15th will be paid a $0.15 dividend. This represents a $0.60 annualized dividend and a dividend yield of 0.33%. The ex-dividend date is Thursday, December 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.19%.
TRADEMARK VIOLATION NOTICE: This article was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2017/12/05/thermo-fisher-scientific-inc-tmo-stake-raised-by-comerica-bank.html.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.